Utilization of Fixed Combination (Budesonide/Formoterol and Salmeterol/Fluticasone and Beclomethasone/Formoterol) in Treatment of Asthma Patients (UFO)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01327001
First received: March 28, 2011
Last updated: July 22, 2011
Last verified: July 2011
  Purpose

Moderate and severe asthma bronchiale is treated by fixed combination (budesonide/formoterol or salmeterol/fluticasone) in the Czech Republic.

There is a hypothesis that doctors should prescribe to each patients per year: six units of fixed combination budesonide/formoterol, or seven units of fixed combination budesonide/formoterol in approach SMART, or twelve units of fixed combination salmeterol/fluticasone. With regard to current prices the treatment by fixed combination budesonide/formoterol should cost less.

The investigators do not have any data about real life utilization of fixed combination in asthma treatment in Czech Republic The investigators propose to conduct a non-interventional multicentric retrospective epidemiological study looking into the patients records kept by specialist - allergists and pulmologists.

Retrospective data for eligible patients will be reviewed by participating investigators, physicians taking care of their patients, and recorded in the electronic CRF. Only patients who have been treated for asthma bronchiale (classification of severity - moderate or severe persistent asthma) with fixed combination for at least one year could be included into the study. There are no scheduled visits for any patient participating in the study.


Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Utilization of Fixed Combination (Budesonide/Formoterol and Salmeterol/Fluticasone and Beclomethasone/Formoterol) in Treatment of Asthma Patients in Real Life Condition in Czech Republic (UFO)

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Number of packs of fixed combination prescribed to patients with asthma bronchiale in one year [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Asthma severity in patients treated with fixed combination [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Strength/dose of prescribed fixed combination [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 2815
Study Start Date: April 2011
Study Completion Date: June 2011
  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Primary care clinic (specialists in allergology and pulmology)

Criteria

Inclusion Criteria:

  • Male or female aged 6 years or over
  • Asthma bronchiale, classification of severity - moderate or severe persistent
  • Documented fixed combination (budesonide/formoterol or salmeterol/fluticasone) therapy for at least 18 months
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01327001

  Hide Study Locations
Locations
Czech Republic
Research Site
Benesov, Czech Republic
Research Site
Beroun, Czech Republic
Research Site
Bilovec, Czech Republic
Research Site
Blansko, Czech Republic
Research Site
Blovice, Czech Republic
Research Site
Bohumin, Czech Republic
Research Site
Brandys N/L, Czech Republic
Research Site
Brno, Czech Republic
Research Site
Caslav, Czech Republic
Research Site
Ceska Lipa, Czech Republic
Research Site
Ceske Budejovice, Czech Republic
Research Site
Cesky Krumlov, Czech Republic
Research Site
Cesky Tesin, Czech Republic
Research Site
Cheb, Czech Republic
Research Site
Chomutov, Czech Republic
Research Site
Chotebor, Czech Republic
Research Site
Chrudim, Czech Republic
Research Site
Decin, Czech Republic
Research Site
Domazlice, Czech Republic
Research Site
Fifejdy Ostrava, Czech Republic
Research Site
Frydek Mistek, Czech Republic
Research Site
Havirov, Czech Republic
Research Site
Havlickuv Brod, Czech Republic
Research Site
Holice, Czech Republic
Research Site
Horazdovice, Czech Republic
Research Site
Horovice, Czech Republic
Research Site
Hradec Kralove, Czech Republic
Research Site
Hranice, Czech Republic
Research Site
Jablonec N/N, Czech Republic
Research Site
Jilemnice, Czech Republic
Research Site
Jindrichuv Hradec, Czech Republic
Research Site
Kadan, Czech Republic
Research Site
Karlovy Vary, Czech Republic
Research Site
Karvina, Czech Republic
Research Site
Kladno, Czech Republic
Research Site
Klatovy, Czech Republic
Research Site
Kolin, Czech Republic
Research Site
Kralupy N/V, Czech Republic
Research Site
Krnov, Czech Republic
Research Site
Kromeriz, Czech Republic
Research Site
Kutna Hora, Czech Republic
Research Site
Liberec, Czech Republic
Research Site
Litomerice, Czech Republic
Research Site
Litomysl, Czech Republic
Research Site
Litvnov, Czech Republic
Research Site
Lochovice, Czech Republic
Research Site
Lovosice, Czech Republic
Research Site
MarianskeLazne, Czech Republic
Research Site
Melnik, Czech Republic
Research Site
Mlada Boleslav, Czech Republic
Research Site
Mnichovo Hradiste, Czech Republic
Research Site
Most, Czech Republic
Research Site
Nachod, Czech Republic
Research Site
Neratovice, Czech Republic
Research Site
Nove Mesto na Morave, Czech Republic
Research Site
Novy Jicin, Czech Republic
Research Site
Olomouc, Czech Republic
Research Site
Opava, Czech Republic
Research Site
Orlova, Czech Republic
Research Site
Ostrava, Czech Republic
Research Site
Ostrava - Hrabuvka, Czech Republic
Research Site
Pardubice, Czech Republic
Research Site
Pelhrimov, Czech Republic
Research Site
Pisek, Czech Republic
Research Site
Plzen, Czech Republic
Research Site
Podebrady, Czech Republic
Research Site
Prachatice, Czech Republic
Research Site
Praha, Czech Republic
Research Site
Prerov, Czech Republic
Research Site
Pribor, Czech Republic
Research Site
Pribram, Czech Republic
Research Site
Prostejov, Czech Republic
Research Site
Prostejov - Karlov, Czech Republic
Research Site
Rakovnik, Czech Republic
Research Site
Roudnice N/L, Czech Republic
Research Site
Roznov pod Radhostem, Czech Republic
Research Site
Rychnov nad Kneznou, Czech Republic
Research Site
Slany, Czech Republic
Research Site
Sokolov, Czech Republic
Research Site
Stod, Czech Republic
Research Site
Strakonice, Czech Republic
Research Site
Sumperk, Czech Republic
Research Site
Svitavy, Czech Republic
Research Site
Tabor, Czech Republic
Research Site
Tachov, Czech Republic
Research Site
Teplice, Czech Republic
Research Site
Trebic, Czech Republic
Research Site
Tremosna, Czech Republic
Research Site
Trutnov, Czech Republic
Research Site
Tyn nad Vltavou, Czech Republic
Research Site
Usti nad Labem, Czech Republic
Research Site
Valasske Mezirici, Czech Republic
Research Site
Vsetin, Czech Republic
Research Site
Vyskov, Czech Republic
Research Site
Zamberk, Czech Republic
Research Site
Zatec, Czech Republic
Research Site
Zdar nad Sazavou, Czech Republic
Research Site
Zelezny Brod, Czech Republic
Research Site
Zlin, Czech Republic
Research Site
Znojmo, Czech Republic
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Viktor Kasak, MD LERYMED spol. s.r.o.
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT01327001     History of Changes
Other Study ID Numbers: NIS-RCZ-SYM-2010/1
Study First Received: March 28, 2011
Last Updated: July 22, 2011
Health Authority: Czech Republic: State Institute for Drug Control

Keywords provided by AstraZeneca:
Asthma bronchiale, fixed combination

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Fluticasone
Beclomethasone
Budesonide
Formoterol
Salmeterol
Symbicort
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists

ClinicalTrials.gov processed this record on April 21, 2014